Table 1.
Demographic and relevant clinical characteristics of study participants
| Characteristic | No retinopathy | Retinopathy |
|---|---|---|
| N | 21 | 10 |
| Age (years) | 66 (55, 78) | 61 (41, 72) |
| Sex | F:M=19:2 | F:M=10:0 |
| Height (cm) | 165.1 (160.0, 171.5) | 165.1 (162.6, 167.6)a |
| Weight (kg) | 74 (62, 83) | 61 (58, 79)a |
| Daily dose (mg) | 400 (200, 400) | 400 (400, 400) |
| Adjusted daily dose (mg/kg/d) | 5.6 (3.5, 6.3) | 6.5 (6.2, 6.8) |
| Toxic dosing (%) | 19.0 | 62.5 |
| Duration (years) | 6.7 (3.6, 12.1) | 15.4 (10.4, 25.3) |
| Cumulative dose (g) | 876 (427, 1,540) | 2015 (1,424, 3,869)a |
| Renal disease (number of patients) | 0 | 1 |
| Liver disease (number of patients) | 0 | 0 |
| Number of VFs | 7 (4, 10) | 7 (4, 11) |
| Number of reliable VFs | 6 (4, 9) | 6 (4, 10) |
Notes: Adjusted daily dose equals the daily dose divided by the lesser of the actual weight (in kg) and the ideal body weight (in kg). Values in parentheses represent the interquartile range, which is preceded by the median.
a
For certain characteristics, data were missing from the clinical chart, such that the sample size for the cell is different; an=9.
Abbreviations: F, female; M, male; N, number of patients; VF, visual field.